Fosun Wanbang Company Profile

What is the competitive landscape for FOSUN WANBANG

FOSUN WANBANG has five approved drugs.

Summary for Fosun Wanbang

US Patents:	0
Tradenames:	5
Ingredients:	5
NDAs:	5

Drugs and US Patents for Fosun Wanbang

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Fosun Wanbang	GUANFACINE HYDROCHLORIDE	guanfacine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	217638-003	Jun 12, 2024		DISCN	No	No
Fosun Wanbang	GUANFACINE HYDROCHLORIDE	guanfacine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	217638-002	Jun 12, 2024		DISCN	No	No
Fosun Wanbang	MYCOPHENOLIC SODIUM	mycophenolic sodium	TABLET, DELAYED RELEASE;ORAL	216637-002	May 29, 2024	AB	RX	No	No

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Fosun Pharma
• Fosun Wanbang

Fosun Wanbang Market Analysis and Financial Projection

Based on the search results provided, here is a pharmaceutical competitive landscape analysis for Fosun Wanbang, focusing on their market position, key strengths, and strategic insights:

Market Position

Fosun Wanbang (also known as Wanbang Biopharmaceuticals) is a core subsidiary of Shanghai Fosun Pharmaceutical Group, one of the leading pharmaceutical companies in China. Some key points about their market position:

• Established in 1981, Wanbang Biopharma has grown to become a major player in China's pharmaceutical industry[5].

• In 2020, Wanbang had 7 products with #1 domestic market share in China and 13 products with annual sales exceeding 100 million RMB[13].

• Focuses primarily on the diabetes therapeutic area as its core field, with additional strengths in cardiovascular, endocrine and anti-tumor drugs[9].

• Has established a nationwide marketing network in China with over 3,000 sales personnel[5].

Key Strengths

1. R&D Capabilities:

   • Invests about 10% of sales revenue annually into R&D[5].
   • Has a R&D team of over 400 personnel, with over 50% holding advanced degrees[5].
   • Files for over 50 national patents annually[5].

2. Manufacturing:

   • Operates 7 manufacturing bases across China[5].
   • Multiple production lines have passed international regulatory inspections (FDA, EU)[5].

3. Product Portfolio:

   • Strong presence in diabetes, with animal insulin, recombinant human insulin and insulin analogs[15].
   • Leading products in other therapeutic areas like cardiovascular (heparin preparations), metabolism (febuxostat), and oncology[15].

4. International Partnerships:

   • Has formed partnerships with international companies for drug development and commercialization[1][12].

5. Backing of Fosun Pharma:

   • As a subsidiary of Fosun Pharma, benefits from the parent company's resources and capabilities[5].

Strategic Insights

1. Focus on Innovation: Wanbang is transitioning from a marketing-driven to an innovation and marketing dual-driven model[12]. This aligns with the broader strategy of Fosun Pharma to increase revenue from innovative products[6].

2. Expanding Therapeutic Areas: While maintaining leadership in diabetes, Wanbang is expanding into other high-value areas like oncology and immunology[15].

3. International Expansion: Partnering with foreign companies for drug development and exploring opportunities in overseas markets[1][12].

4. Digital Transformation: As part of Fosun Pharma, likely exploring digital health solutions and online-offline integrated service models[6].

5. Vertical Integration: Operates across the value chain from API manufacturing to finished dosage forms and commercialization[15].

6. Social Responsibility: Actively engages in corporate social responsibility initiatives, which can enhance brand reputation[5].

7. Competitive Intelligence: Like other leading pharma companies, Wanbang likely employs sophisticated competitive intelligence and benchmarking practices to inform strategy[14].

In conclusion, Fosun Wanbang has established a strong position in the Chinese pharmaceutical market, particularly in diabetes care. Its focus on innovation, backed by significant R&D investments and the resources of Fosun Pharma, positions it well for future growth. However, it faces intense competition in a rapidly evolving market landscape, necessitating continued strategic focus on innovation, market expansion, and operational excellence.